PureTech Ventures launched Celea, a new respiratory disease treatment, with Sven Dethlefs appointed to lead its program advancement.
2 reports, 1 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PureTech Ventures launched Celea, a new respiratory disease treatment, with Sven Dethlefs appointed to lead its program advancement.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Leadership appointments at PureTech Ventures include the appointment of Robert Lyne as Interim CEO and Sharon Barber-Lui as Interim Chair of the Board.Sub-event
PureTech launched Celea for respiratory disease treatment, led by Dethlefs (ex-Teva CEO).1 source
Keep exploring
The entities involved
-
PureTech Ventures
american company
Nothing else this week.
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Coverage
Newest first; wire copies grouped- Business WirePureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea BOSTON, August 12